TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
Dr. Reddy’s Laboratories announced its participation in several investor conferences scheduled for late November 2025. These meetings, organized by Investec, Citi, and HSBC, will take place in Mumbai, Hyderabad, and Hong Kong, respectively, and involve in-person group meetings with institutional investors. The participation in these conferences underscores Dr. Reddy’s commitment to engaging with investors and providing updates on its strategic initiatives, potentially impacting its market perception and investor relations.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company based in Hyderabad, India. The company is involved in the manufacture and marketing of a wide range of pharmaceuticals and is focused on providing affordable and innovative medicines for healthier lives. It operates in various international markets, including the United States, India, and Europe.
Average Trading Volume: 1,016,792
Technical Sentiment Signal: Hold
Current Market Cap: $11.72B
Learn more about RDY stock on TipRanks’ Stock Analysis page.